Ann Bass

2.0k total citations
27 papers, 749 citations indexed

About

Ann Bass is a scholar working on Pathology and Forensic Medicine, Rheumatology and Immunology. According to data from OpenAlex, Ann Bass has authored 27 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 11 papers in Rheumatology and 8 papers in Immunology. Recurrent topics in Ann Bass's work include Multiple Sclerosis Research Studies (15 papers), Systemic Lupus Erythematosus Research (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Ann Bass is often cited by papers focused on Multiple Sclerosis Research Studies (15 papers), Systemic Lupus Erythematosus Research (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Ann Bass collaborates with scholars based in United States, Germany and United Kingdom. Ann Bass's co-authors include David Margolin, Alasdair Coles, Krzysztof Selmaj, D. A. S. Compston, Edward Fox, Vesna Brinar, Anton Vladić, Stephen Lake, Susan Moran and Suzanne Gazda and has published in prestigious journals such as The Journal of Immunology, Neurology and The Lancet Neurology.

In The Last Decade

Ann Bass

26 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Bass United States 14 524 247 200 188 180 27 749
Florence Casset‐Semanaz Switzerland 8 423 0.8× 114 0.5× 157 0.8× 193 1.0× 165 0.9× 11 566
Joseph D. Croft United States 6 330 0.6× 213 0.9× 164 0.8× 58 0.3× 87 0.5× 9 802
Dina Attias Israel 16 205 0.4× 210 0.9× 218 1.1× 73 0.4× 67 0.4× 46 864
T. Kinoshita Japan 11 372 0.7× 176 0.7× 465 2.3× 121 0.6× 61 0.3× 26 761
Paul Greaves United Kingdom 10 309 0.6× 311 1.3× 384 1.9× 55 0.3× 21 0.1× 24 731
Radjiv Goulabchand France 13 227 0.4× 160 0.6× 47 0.2× 34 0.2× 179 1.0× 49 615
Kirsten Herbert Australia 14 251 0.5× 128 0.5× 210 1.1× 146 0.8× 21 0.1× 26 684
M H Cardiel Mexico 14 279 0.5× 365 1.5× 41 0.2× 55 0.3× 754 4.2× 18 1.0k
S. Rist France 9 107 0.2× 80 0.3× 49 0.2× 90 0.5× 272 1.5× 17 521
G Stark United Kingdom 8 251 0.5× 113 0.5× 196 1.0× 70 0.4× 47 0.3× 12 471

Countries citing papers authored by Ann Bass

Since Specialization
Citations

This map shows the geographic impact of Ann Bass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Bass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Bass more than expected).

Fields of papers citing papers by Ann Bass

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Bass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Bass. The network helps show where Ann Bass may publish in the future.

Co-authorship network of co-authors of Ann Bass

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Bass. A scholar is included among the top collaborators of Ann Bass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Bass. Ann Bass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ziemssen, Tjalf, Ann Bass, Bart Van Wijmeersch, et al.. (2025). Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. Therapeutic Advances in Neurological Disorders. 18. 4233587663–4233587663. 2 indexed citations
2.
Miravalle, Augusto, Joshua Katz, Derrick Robertson, et al.. (2021). CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple Sclerosis. Neurodegenerative Disease Management. 11(2). 99–111. 6 indexed citations
3.
Lovett‐Racke, Amy E., Yuhong Yang, Yue Liu, et al.. (2021). B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. Journal of Neuroimmunology. 359. 577676–577676. 13 indexed citations
4.
Coles, Alasdair, Douglas L. Arnold, Ann Bass, et al.. (2021). Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders. 14. 1279203702–1279203702. 34 indexed citations
5.
Coles, Alasdair, Joanne Jones, Patrick Vermersch, et al.. (2021). Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal. 28(5). 842–846. 18 indexed citations
6.
Pelletier, Daniel, Douglas L. Arnold, Ann Bass, et al.. (2020). Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up. Multiple Sclerosis Journal. 26. 43–44. 2 indexed citations
7.
Steingo, Brian, Yaser Al Malik, Ann Bass, et al.. (2020). Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. Journal of Neurology. 267(11). 3343–3353. 41 indexed citations
8.
9.
Bass, Ann, Rafael Arroyo, Aaron Boster, et al.. (2020). Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders. 49. 102717–102717. 15 indexed citations
10.
11.
Bass, Ann, Raed Alroughani, Simon Broadley, et al.. (2020). Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study). Griffith Research Online (Griffith University, Queensland, Australia). 94(15). 1 indexed citations
12.
Carruthers, Robert, Anthony Traboulsee, Ann Bass, et al.. (2019). Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology. 10. 253–253. 14 indexed citations
13.
Lovett‐Racke, Amy E., Matthew Gormley, Yue Liu, et al.. (2019). B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology. 332. 187–197. 39 indexed citations
14.
Cuker, Adam, Ann Bass, Čongor Nadj, et al.. (2019). Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Multiple Sclerosis Journal. 26(1). 48–56. 34 indexed citations
15.
16.
Selmaj, Krzysztof, Mario Habek, Ann Bass, et al.. (2017). Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study (P5.338). Neurology. 88(16_supplement). 6 indexed citations
17.
Cuker, Adam, Roberto Stasi, Jeffrey Palmer, et al.. (2014). Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (P2.198). Neurology. 82(10_supplement). 3 indexed citations
18.
Coles, Alasdair, Edward Fox, Anton Vladić, et al.. (2012). Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 78(14). 1069–1078. 193 indexed citations
19.
Coles, Alasdair, Edward Fox, Anton Vladić, et al.. (2011). Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. The Lancet Neurology. 10(4). 338–348. 101 indexed citations
20.
Bass, Ann. (1984). A Survey and Analysis of Computer-Generated/Assisted IEP Management Systems. 1(5). 43–47. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Casset‐Semanaz Breakdown of academic impact, for papers by Joseph D. Croft Breakdown of academic impact, for papers by Dina Attias Breakdown of academic impact, for papers by T. Kinoshita Breakdown of academic impact, for papers by Paul Greaves Breakdown of academic impact, for papers by Radjiv Goulabchand Breakdown of academic impact, for papers by Kirsten Herbert Breakdown of academic impact, for papers by M H Cardiel Breakdown of academic impact, for papers by S. Rist Breakdown of academic impact, for papers by G Stark
Rankless by CCL
2026